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Summary One hundred and twenty-seven consecutive patients presenting with small cell lung cancer were
entered into a whole-brain CT scan surveillance study, starting at presentation and repeating at 3-monthly
intervals for 2 years as an alternative to prophylactic cranial irradiation (PCI). The aim of the study was to
detect CNS metastases at an early asymptomatic stage in the hope that prompt CNS radiotherapy could
achieve long-term control; at the same time unnecessary PCI with its potential long-term morbidity could be
avoided. CNS metastases were found in 56 patients (44%) including 16 (13%) at diagnosis and 40 at a median
of 4 months (range 1-27 months) after completing chemotherapy. No patient developed CNS disease while on
chemotherapy. Thirty-six patients were asymptomatic at diagnosis (group A) but 20 developed clinical CNS
relapse between scans (group B) (interval relapse). Despite prompt radiotherapy 56% of patients in group A
and 60% of patients in group B died with active CNS disease. Likewise, there was no survival difference
between patients in group A, group B or those who never developed CNS disease. Regular 3-month CT scan
surveillance is therefore not an effective substitute for PCI.
Brain metastases are common in patients with small cell lung
cancer (SCLC), occurring in about 10% at presentation, at
least 30% during the course of the illness, and in about 50%
at autopsy (Hirsch et al., 1983; Nugent et al., 1979). CNS
disease contributes significantly to the morbidity of SCLC
(Tobias, 1985; Felletti et al., 1985), especially when local
disease can be controlled and survival improved with
chemotherapy and radiotherapy.
Cranial irradiation can control the clinical features
associated with cerebral metastases in some patients (Nugent
et al., 1979) but is by no means always effective. In our
experience only 50% of patients with symptomatic cranial
metastases achieved useful neurological recovery lasting the
remainder of their lives following cerebral irradiation (Lucas
et al., 1986). In general there is better chance of symptomatic
relief in patients with good neurological function compared
to those with poor neurological function at the start of
treatment (Baglan & Marks, 1981).
An alternative approach has therefore been the use of
prophylactic cranial irradiation (PCI). This has been shown
to reduce the risk of cranial relapse from over 22% to less
than 10% (Pedersen et al., 1988), but has not been associated
with improved survival (Pedersen et al., 1988; Seydel et al.,
1981; Aroney et al., 1983) and carries the risk of short and
long-term morbidity. Acute CNS toxicity (i.e. headache,
nausea, vomiting, fever, cerebral herniation and even death)
is generally seen only after large fraction radiotherapy and
can be avoided by limiting the total dose given (Young et al.,
1974). However, Twijnstra et al. (1987), in a study of patients
before and after treatment with cerebral radiotherapy, de-
scribed abnormalities in standard neurological and mental
function testing in most patients. Chronic CNS toxicity in the
form of abnormal mental status examinations, neuropsycho-
logical tests and computed tomographic (CT) scans has been
detected in several studies of long-term SCLC survivors
treated with cerebral RT, especially with large radiotherapy
fractions and when chemotherapy is given with PCI
(Pedersen et al., 1988; Lee et al., 1986; Johnson et al., 1985).
These problems are of particular concern in that prophylactic
therapy is unnecessary in at least 50% of patients treated, i.e.
those patients who will never develop CNS disease.
We have carried out a study to assess the efficacy of serial
3-monthly CT scanning for the early detection of CNS
disease in asymptomatic patients as an alternative to pro-
phylactic cranial irradiation. It was hoped that the prompt
use of cranial irradiation before symptoms developed would
lead to long-term disease control and a reduction in mor-
bidity in those patients with CNS disease. At the same time
patients without CNS disease would be spared the short and
long-term toxicity associated with PCI. In addition, this
study would allow the time course of the development of
CNS disease in SCLC to be studied in more detail.
Patients and methods
All patients with histologically documented SCLC referred to
the Lung Unit at the Royal Marsden Hospital from March
1986 to May 1988 were entered into a surveillance pro-
gramme. All patients underwent a full neurological history
and examination as part of routine staging prior to treatment
with standard combination chemotherapy. Patients were
assessed at 3-4 weekly intervals while receiving chemo-
therapy and 3-monthly thereafter. Chemotherapy was given
for a maximum of 6 months, or until evidence of progressive
disease. Those patients with limited disease who achieved a
complete remission or good partial remission following
chemotherapy were referred for local chest irradiation (RT)
but did not receive PCI.
CT sections were obtained using a Siemens DRH CT unit
after injection of intravenous contrast medium (50 ml of
300-370mg ml-' iodine) in 4 mm contiguous sections
through the posterior fossa and in 8 mm contiguous sections
to the vertex. Scans were done at presentation and at 3-
monthly intervals thereafter for 2 years. All patients found to
have cerebral metastases were referred immediately for
cranial RT. Those patients who developed neurological
symptoms or signs between scans had interval scans as
indicated and were managed in the same way.
All patients found to have cerebral metastases were com-
menced on dexamethasone 4 mg, four times daily and refer-
red immediately for cranial irradiation (RT). Radiotherapy
policy was to treat patients with whole brain irradiation at a
dose of 40 Gy in 20 fractions, unless this was contra-
indicated because of poor general condition, rapidly advanc-
ing disease or resistance of extra-cranial disease to
chemotherapy. Following cranial RT, all patients underwent
regular neurological assessment in out-patient clinics and
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where possible, continued to have 3-monthly cerebral CT
scans.
Results
One hundred and twenty-seven patients were entered into the
surveillance programme. Their outcome is shown
schematically in Figure 1. Fifty-six of these patients (44%)
were found to have cerebral metastases. In 16 patients (13%)
these were present at diagnosis and in the remaining 40
(31%) these developed at a median of 4 months (range 1-27
months) after completing chemotherapy. No patient de-
veloped CNS disease while receiving chemotherapy.
Thirty-six of the 56 patients (64%) with CNS metastases
were asymptomatic at the time of diagnosis of their cerebral
disease, including nine of the 16 patients detected at original
presentation (group A). At presentation, 28 of these patients
had extensive disease and eight patients limited disease.
Twenty patients were symptomatic at the time of diagnosis
of their cerebral metastases, seven at presentation and 13
who became symptomatic between the 3-monthly CT scans
(interval relapse) (group B). Eighteen of these patients had
extensive disease and two patients limited disease at presenta-
tion.
The median overall survival of the 36 patients in group A
was 12.5 months (range 1-43 + months). Thirty-two of the
36 patients have died. Of these, seven patients never received
cranial RT because of rapidly advancing disease or poor
general condition. Fourteen of the remaining 25 (56%)
developed recurrent CNS disease despite cranial RT, or died
within 1 month of completing RT. Ten patients (40%) died
with no evidence of cerebral disease. The CNS status of one
patient at the time of death is unknown.
The median survival of the 20 patients in group B was 10
months (range 3-33 months). All patients received cranial
RT and all have died. Twelve of these patients (60%) died
with active CNS disease or within 1 month of cerebral RT.
There was no evidence of CNS disease at the time of death in
four patients and CNS status at the time of death is un-
known in four patients.
The median survival of the 71 patients who never
developed CNS disease (as assessed by serial CT scans for 2
years, and subsequent clinical observation in one patient for
a further 5 months; group C) was 9 months (range 1-53
months) (Figure 2).
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Figure 2 Overall survival. , group A (36 patients), asympto-
matic at time of diagnosis of CNS disease. ----, group B (20
patients), symptomatic at time of diagnosis of CNS disease.
-, group C (71 patients), no CNS disease.
Discussion
The main aim of this study was to determine whether sequen-
tial CT brain scanning of patients with SCLC and the
prompt treatment of metastases diagnosed at a pre-
symptomatic stage could prevent the morbidity associated
with CNS disease, without the problems of 'over-treatment'
associated with PCI. Our results have shown that this ap-
proach is unsuccessful. Regular CT scanning failed to detect
pre-symptomatic disease in one-third of patients who
developed CNS metastases (interval relapses). The outcome
of these patients was poor in that despite subsequent
radiotherapy 12/20 (60%) died with clinically active CNS
disease. Moreover, the early detection of asymptomatic CNS
disease did not affect the outcome, in that despite prompt
radiotherapy more than 50% of the patients who have since
died had active CNS disease with its associated morbidity at
the time of death. Indeed these patients fared almost as badly
as those with interval relapses.
Other studies have given conflicting results on the success
of therapeutic cranial irradiation in the control of active CNS
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Figure 1 Outcome of patients with CNS disease NA = not assessable, CT = chemotherapy, RT = radiotherapy.
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disease. Nugent et al. (1979) reported a 92% palliation rate
in patients completing palliative radiation, but 25% of the
patients in the study died before completing radiotherapy.
Baglan et al. (1981) reported that 64% of patients with CNS
disease had complete resolution of their neurological signs
and symptoms for the remainder of their life following cere-
bral irradiation. They also reported an inverse correlation
between the severity of neurological symptoms and the
degree of palliation achieved.
Other studies have shown that less than 50% of patients
with clinically active cerebral metastases achieved lasting
benefit with cranial radiotherapy. Cox et al. (1980) treated 40
patients with cerebral metastases with cranial radiotherapy.
This resulted in a complete response in 37.5% of patients and
a PR in a further 37.5%, but eight patients failed to complete
radiotherapy and only seven patients lived for more than 12
months from radiotherapy. Survival was the same for those
presenting with brain metastases and in those who subse-
quently developed cerebral disease. Of 39 patients with cere-
bral metastases treated with dexamethasone and radiotherapy
by Lucas and colleagues (1986), only eight patients (20%)
achieved a complete neurological recovery, with useful pallia-
tion (PR) in a further ten patients (27%). In a quality of life
study by Felleti et al. (1985) the onset of brain metastases
was associated with a fall in performance status and
radiotherapy was shown to be relatively ineffective in im-
proving performance status once this deterioration had
occurred.
This study also allowed us to gain detailed information on
the natural history of CNS disease in a closely followed
group of 127 patients. The 44% incidence of CNS disease is
in accordance with the previously reported clinical incidence
of around 30% and the autopsy incidence of around 50%
(Hirsch et al., 1983; Nugent et al., 1979; Komaki et al.,
1981). However, it was of interest that these patients present-
ed in two discrete clusters, first at the time of diagnosis and
second at a median of 4 months after completing
chemotherapy. No patient developed clinical or radiological
evidence of CNS disease during chemotherapy. This observa-
tion fits with recent reports suggesting that chemotherapy is
effective in the treatment of cerebral metastases from SCLC
(Kantarjian et al., 1984; Twelves et al., 1990; Kristjansen et
al., 1988) and that the response rate at this site is the same as
at other extra-cranial sites of disease (Twelves et al., 1990).
Despite these encouraging observations, it is unlikely that
maintenance chemotherapy would significantly delay the
development of CNS disease since resistance would be
anticipated here as at other sites.
Finally, the survival of patients with CNS disease detected
by CT scan surveillance was no worse than that for patients
who never developed CNS disease, confirming previous
observations (Hirsch et al., 1983; Vincent et al., 1987; Crane
et al., 1984) and reinforcing the point that the principal cause
of death in SCLC is uncontrollable systemic metastases.
In conclusion, regular CT brain scan surveillance, even as
frequently as at 3-month intervals and followed by prompt
CNS radiotherapy, is not an effective approach to the prob-
lem of CNS metastases in small cell lung carcinoma.
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